The Power of Radiotherapy

The Specificity of Molecular Targeting

for Better
Patient Outcomes

Because Cancer Patients
Need a New Approach


Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic  identifies the patients with the corresponding molecular signature who are the best candidates for therapy.


Targeted Therapies
for Personalized Medicine

Peptide targeted radiotherapy is a promising new approach to cancer therapy and has been widely validated in clinical studies as well as in routine clinical use in Europe. Treating cancer with radiotherapy can achieve results not possible with conventional therapies because cancer cells are unable to evade the lethal damage caused by targeted radiation.

News & Events

Andarix Pharmaceuticals’ Targeted Therapy Demonstrates Efficacy in Pancreatic Cancer

Dec 2, 2014

Tozaride Demonstrates Pancreatic Tumor Reduction in Animal Model ANDARIX Pharmaceuticals, a clinical stage company, announced today the publication of research findings that demonstrate the ability of its Tozaride targeted peptide therapy to reduce the size of pancreatic cancer tumors. The research paper titled “The Somatostatin Analog Rhenium Re-188-P2045 Inhibits the Growth of AR42J Pancreatic Tumor-Xenografts”…

Read More

Andarix Pharmaceuticals Selected to Present at International Drug Conference in Copenhagen

Sep 17, 2014

ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the Orphan Drugs Summit to be held in Copenhagen, Denmark from September 17-19, 2014. Conference agenda information are available at Mr. Adams will highlight recent results…

Read More

Andarix Pharmaceuticals Receives Pancreatic Cancer Orphan Drug Designation from the FDA

Jul 6, 2014

Targeted therapy for pancreatic cancer is based on personalized medicine approach ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung cancer announced today that Tozaride, the Company’s lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the…

Read More